ROCHE HOLDING AG

ROG
Delayed Quote. Delayed  - 11/26 11:31:16 am
358.6CHF -0.95%

Press Release : New four-year data show Roche's -2-

10/14/2021 | 01:03am

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

*Relapse associated with low likelihood of recovery, resulting in permanent disability

Roche Group Media Relations

Phone: +41 61 688 8888 / e-mail: media.relations@roche.com https://www.globenewswire.com/Tracker?data=PQ18mNy5E8aRfAAj5YOqTKMHx2PMwRg_F8QwFN0RfAcTDMcchw8SsBLbOvfYAYDOsabbAdoto86wT4ixCq837lvUThMCtu2wjWPeEv5JLjHscAfXhAiwUZMl-lstlral

 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Barbara von Schnurbein  Karsten Kleine 
 Phone: +41 61 687 89 67     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
 Sileia Urech 
 Phone: +41 79 935 81 48 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: +41 61 68-78503                        Phone: +41 61 68-83894 
 e-mail: mailto:karl.mahler@roche.com          e-mail: jon_kaspar.bayard@roche.com 
 karl.mahler@roche.com 
--------------------------------------------  -------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: +41 61 68-88027                        Phone: +41 61 68-75284 
 e-mail: mailto:sabine.borngraeber@roche.com   e-mail: bruno.eschli@roche.com 
 sabine.borngraeber@roche.com 
--------------------------------------------  -------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: +41 61 68-84814                        Phone: +41 61 68-72942 
 e-mail: mailto:birgit.masjost@roche.com       e-mail: mailto:gerard.tobin@roche.com 
 birgit.masjost@roche.com                      gerard.tobin@roche.com 
--------------------------------------------  -------------------------------------- 
 
Investor Relations North America 
Loren Kalm 
 Phone: +1 650 225 3217 
 e-mail: mailto:kalm.loren@gene.com 
 kalm.loren@gene.com 
-------------------------------------------- 
 

Attachment

   -- 14102021_MR_Enspryng_SAkuraStar and SAkuraSky_en 
      https://ml-eu.globenewswire.com/Resource/Download/93a693ac-8012-46fb-8dfa-af5c69d5d5d5 
 
 
 

(END) Dow Jones Newswires

October 14, 2021 01:03 ET (05:03 GMT)

Copier lien
All news about ROCHE HOLDING AG
1d ago
1d ago
1d ago
1d ago
1d ago